Bupropion has a reputation among prescribers as the antidepressant that does not interfere with sex. That reputation is mostly earned — it is the drug most often reached for when someone on an SSRI cannot orgasm, or cannot orgasm without difficulty. But "mostly" is doing real work in that sentence, and the evidence splits into two questions that are not equally well answered:

  • Does bupropion cause sexual side effects? The evidence here is strong, and the answer is largely no.
  • Does bupropion fix sexual side effects caused by another antidepressant? The evidence here is real but mixed, and the trials disagree with each other in a way that is worth understanding.

This article covers both. It is not medical advice, and nothing here is a reason to change how you take a prescription.

Why bupropion behaves differently

Most antidepressants that cause orgasm problems work by increasing serotonin signalling, and serotonin is directly involved in the reflex that produces orgasm. Bupropion is not one of those drugs: it acts on noradrenaline and dopamine reuptake instead and does not block serotonin reuptake. That mechanistic difference is the reason its sexual side-effect profile looks different from the SSRIs — not a marketing claim, but a distinction that shows up consistently in the trial data.

What it does to sexual function on its own

In a cross-sectional study of 6,297 patients across 1,101 US primary care clinics, bupropion immediate-release and sustained-release had the lowest rates of sexual dysfunction of any antidepressant measured — around 22–25%, against 36–43% for SSRIs, mirtazapine and venlafaxine extended-release (Clayton et al., 2002).

A meta-analysis limited to studies that asked about sexual function directly found no statistically significant difference from placebo for bupropion (Serretti & Chiesa, 2009). Clinical reviews of the field consistently place it in the lowest-risk group, alongside moclobemide, agomelatine and reboxetine (Rothmore, 2020).

The head-to-head trial

The cleanest evidence comes from two identically designed randomised trials that compared bupropion extended-release against escitalopram and placebo in 829 adults with moderate to severe depression and normal sexual function at the start. Orgasm dysfunction was the pre-specified primary endpoint (Clayton et al., 2006).

At eight weeks, orgasm dysfunction occurred in 13% and 16% of patients on bupropion across the two studies, against 32% and 29% on escitalopram. Bupropion was statistically indistinguishable from placebo, while escitalopram was significantly worse. When sexual function is the deciding factor between two otherwise comparable drugs, that is about as clear as this kind of evidence gets.

Where the evidence is weaker

The harder question is whether bupropion reverses sexual dysfunction that an SSRI has already caused. Here the trials genuinely disagree, and the disagreement is instructive rather than confusing.

  • Positive: a double-blind trial in 218 women aged 25–45 with SSRI-induced sexual dysfunction found adjunctive bupropion sustained-release at 150 mg twice daily improved sexual function scores substantially over placebo (Safarinejad, 2011).
  • Negative: a double-blind trial in 41 patients using 150 mg once daily found no significant improvement over placebo on any measure (DeBattista et al., 2005).
  • Too small to settle it: a pilot study in 11 adults who switched from an SSRI to bupropion reported improvement, but only 6 patients completed eight weeks (Clayton et al., 2001).

The pattern across those three trials is a dose difference — 300 mg a day helped, 150 mg a day did not — but that reading comes from comparing separate small studies, not from a trial designed to test it. It is a plausible explanation, not a demonstrated one. The honest position is that bupropion helps in some people, the effect depends on how it is used, and it is not a guaranteed fix.

Why "just switch" is not a trivial decision

Because several antidepressants are comparably effective (Cipriani et al., 2018), sexual side effects often can be addressed by changing drug rather than abandoning treatment. But switching has its own costs: a period of adjustment, the risk that the new drug does not work as well for you, and discontinuation effects from the old one. Adding bupropion alongside an SSRI is a different strategy with a different evidence base from replacing the SSRI with bupropion, and the two are not interchangeable.

That is a conversation to have with a prescriber who knows your history. What you can bring to it is a description of what actually changed and when — which is more useful than a general impression, and much more useful than trying to remember how last spring compared to this one.

What to record if you are making a change

Bupropion's effects are slow and its titration is gradual, which makes this exactly the situation where a written record beats memory:

  • Note the date and dose of each change, including the taper of anything you are coming off.
  • Rate orgasm consistently, using the same scale each time.
  • Track the phases separately — desire, arousal and orgasm can move independently, and a drug can help one while leaving another unchanged.
  • Give it weeks, not days. Anything shorter is mostly noise.

If orgasm problems began on an SSRI rather than bupropion, the companion article on SSRI sexual side effects covers that class in detail, and medication and orgasm covers the wider picture across drug classes.

The short version

Bupropion is the antidepressant least likely to interfere with orgasm, and the evidence for that is solid — including a head-to-head trial where it was indistinguishable from placebo while escitalopram was clearly worse. Whether it repairs sexual dysfunction already caused by another antidepressant is a genuinely open question: the positive result came at double the dose of the negative one, in a much smaller body of evidence than most people assume. It is a well-founded option, not a certainty, and it is worth approaching with a record rather than a recollection.

Sources

  1. Clayton, A. H., Croft, H. A., Horrigan, J. P., et al. (2006). Bupropion Extended Release Compared with Escitalopram: Effects on Sexual Functioning and Antidepressant Efficacy in 2 Randomized, Double-Blind, Placebo-Controlled Studies. Journal of Clinical Psychiatry, 67(5), 736–746. (829 patients with moderate to severe depression and normal sexual function at baseline; orgasm dysfunction was the primary endpoint.) https://doi.org/10.4088/jcp.v67n0507
  2. Clayton, A. H., Pradko, J. F., Croft, H. A., et al. (2002). Prevalence of Sexual Dysfunction Among Newer Antidepressants. Journal of Clinical Psychiatry, 63(4), 357–366. (6,297 patients across 1,101 US primary care clinics; bupropion immediate- and sustained-release showed the lowest rates.) https://doi.org/10.4088/jcp.v63n0414
  3. Serretti, A., & Chiesa, A. (2009). Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis. Journal of Clinical Psychopharmacology, 29(3), 259–266. (Found no statistically significant difference from placebo for bupropion, mirtazapine, moclobemide, agomelatine, amineptine or nefazodone.) https://doi.org/10.1097/JCP.0b013e3181a5233f
  4. DeBattista, C., Solvason, B., Poirier, J., et al. (2005). A Placebo-Controlled, Randomized, Double-Blind Study of Adjunctive Bupropion Sustained Release in the Treatment of SSRI-Induced Sexual Dysfunction. Journal of Clinical Psychiatry, 66(7), 844–848. (A negative trial: 41 patients, 150 mg/day, no significant improvement over placebo. Included here because the positive trials used higher doses.) https://doi.org/10.4088/jcp.v66n0706
  5. Safarinejad, M. R. (2011). Reversal of SSRI-Induced Female Sexual Dysfunction by Adjunctive Bupropion in Menstruating Women: A Double-Blind, Placebo-Controlled Study. Journal of Psychopharmacology, 25(3), 370–378. (218 women aged 25–45, 12 weeks, bupropion sustained-release 150 mg twice daily.) https://doi.org/10.1177/0269881109351966
  6. Clayton, A. H., McGarvey, E. L., Abouesh, A. I., et al. (2001). Substitution of an SSRI with Bupropion Sustained Release Following SSRI-Induced Sexual Dysfunction. Journal of Clinical Psychiatry, 62(3), 185–190. (Very small pilot study — 11 adults, of whom 6 completed 8 weeks. Directional only.) https://doi.org/10.4088/jcp.v62n0309
  7. Cipriani, A., Furukawa, T. A., Salanti, G., et al. (2018). Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults with Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. The Lancet, 391(10128), 1357–1366. (All 21 drugs were more effective than placebo; differences between them were mostly modest.) https://doi.org/10.1016/S0140-6736(17)32802-7
  8. Rothmore, J. (2020). Antidepressant-Induced Sexual Dysfunction. Medical Journal of Australia, 212(7), 329–334. (Concludes sexual dysfunction risk is lowest with moclobemide, agomelatine, reboxetine and bupropion.) https://doi.org/10.5694/mja2.50522